J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
TL;DR: The preclinical and clinical development of CTLA-4-blocking antibodies are reviewed and current practices using ipilimumab for the treatment of advanced melanoma are described, including the remarkable durability of responses and a distinct side-effects profile.
Journal ArticleDOI
TNF in the era of immune checkpoint inhibitors: friend or foe?
TL;DR: In this paper, the authors discuss clinical and preclinical studies that address the relationship between TNF, TNF inhibition and cancer, and suggest that at least short courses of TNF inhibitors are safe for the treatment of irAEs in patients with cancer undergoing ICI therapy.
Journal ArticleDOI
Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
Jose Lutzky,Jedd D. Wolchok,Omid Hamid,C. Lebbé,Hubert Pehamberger,Gerald P. Linette,V. de Pril,Ramy Ibrahim,Axel Hoos,Steven J. O'Day +9 more
TL;DR: DC and survival benefits with ipilimumab are observed among patients with advanced melanoma that develop an irAE and among pts that do not develop anirAE, and pts who do not experience an ir AE may still demonstrate clinical benefit with ipILimumab.
Journal ArticleDOI
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
TL;DR: Research is warranted to establish how immunotherapeutic agents can be combined with conventional agents, with each other or with molecularly targeted agents such as vemurafenib, to further optimise clinical outcomes.
Journal ArticleDOI
Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
TL;DR: In this paper, Ipilimumab, an anti-CTLA-4 monoclonal antibody, induces durable survival benefits in advanced melanoma patients in 4 Phase II studies.